Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.


Sai Life Sciences joins the global ‘COVID Moonshot’ project

Sai Life Sciences, today announced its collaboration with the COVID Moonshot project that aims to deliver an antiviral drug candidate effective against COVID-19. With an in-kind contribution of a team of Medicinal Chemists and supporting infrastructure, Sai Life Sciences will help synthesize and profile analogues for NCEs and other previously known compounds tested for other viruses.

PostEra, a biotechnology company specialising in machine learning for drug discovery, is leading the initiative. Joining them are leading experts in the fields of computational drug discovery, chemical synthesis and biochemical assays. In the three months since its start in February this year, the team has already identified over 60 experimentally-confirmed ‘fragments’ that effectively target a key protein associated with COVID-19. It has now opened a crowdsourcing initiative to accelerate the design of potential drug candidates from these fragments and received over 4000 submissions from contributors around the world.

Welcoming Sai Life Sciences into the consortium, CEO of PostEra Aaron Morris, said, "We are immensely grateful for Sai Life Sciences’ contribution to this project. They are helping take the most promising crowdsourced ideas from the Moonshot platform and turning these ideas into chemical reality. It is generosity like this that gives us hope that this moonshot of a project could achieve something ground-breaking in our search for an effective COVID antiviral.”

Speaking about its participation in the project, CEO & Managing Director of Sai Life Sciences, Krishna Kanumuri said, “We are delighted to join this important global initiative. The consortium approach to finding treatments for patients in the fight against COVID-19 is a worthy cause and something that aligns very well with our purpose of working with partners to accelerate solutions for improving life.”

Over the past two decades, Sai Life Sciences has built up a portfolio of NCE Discovery services on the foundation of a strong chemical synthesis platform. The company today offers innovator biotechs and pharmaceutical companies the full spectrum of Discovery services from Target ID & Validation through till IND, in addition to a robust suite of capabilities across NCE development and cGMP manufacturing.

Share article

More News


Sai Life Silver Jubilee year

Sai Life Sciences enters its Silver Jubilee year; surpasses vision of 25 commercial molecules by 2025

Sai Life Sciences entered its Silver Jubilee year with aplomb, surpassing its vision of supporting global innovator partners in bringing 25 new medicines to market by 2025. The company crossed this milestone two years ahead of schedule and is poised to sustain this momentum on the back of a strong portfolio of molecules at various […]
Read more



Sai Life Sciences joins Science Based Targets initiative (SBTi), commits to fight climate change with Science

To help combat climate change, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), announced joining Science Based Targets initiative (SBTi), a global body enabling businesses to set ambitious emission reduction targets in line with the latest climate science. Accordingly, it has committed to set near-term company-wide emission reductions in line with […]
Read more


Commitment to Sustainability

Sai Life Sciences reaffirms commitment to Sustainability, charts out SDGs to be achieved by FY27

On the World Environment Day 2023, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), announced its renewed Sustainable Development Goals (SDG) charting out the roadmap to achieve specific environmental, social and governance (ESG) targets by the financial year ending March 31, 2027. Making the announcement, Krishna Kanumuri, CEO & Managing Director, […]
Read more


SSRL inauguration

Sai Life Sciences opens SSRL, a dedicated research facility for Schrödinger, at its Hyderabad R&D Campus

• Fully equipped labs with 75-member team set-up and made operational in <100 days Sai Life Sciences, one of India’s fastest growing global Contract Research, Development & Manufacturing Organisations (CRO-CDMO), today announced the opening of Sai Schrödinger Research Laboratories (SSRL) at its R&D campus in Hyderabad, India. The facility was inaugurated by Dr. Karen Akinsanya, […]
Read more


Sai Life Sciences & NIIT Foundation

Sai Life Sciences and NIIT Foundation partner to create livelihood opportunities for underserved communities in Hyderabad

Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRO-CDMO), today announced entering into an agreement with NIIT Foundation, a not-for-profit education society, to implement youth career development programs for underserved communities in Hyderabad, Telangana. As part of the agreement, NIIT Foundation will develop and run multiple courses, and provide […]
Read more